Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Augmenting Effects of L-DOPS With Carbidopa and Entacapone
This study has been terminated.
Study NCT00547911 Information provided by National Institutes of Health Clinical Center (CC)
First Received on October 19, 2007. Last Updated on May 3, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Parkinson Disease
Multiple System Atrophy
Autonomic Nervous System Diseases
Additional conditions recognized in this trial
Atrophy
Nervous System Diseases
Primary Dysautonomias
Shy-Drager Syndrome
More general conditions related to this trial
Basal Ganglia Diseases
Brain Diseases
Cardiovascular Diseases
Central Nervous System Diseases
Hypotension
Movement Disorders
Neurodegenerative Diseases
Parkinsonian Disorders
Pathological Conditions, Anatomical
Vascular Diseases
Interventions listed in this trial
L-DOPS
Additional drug interventions recognized in this trial
Carbidopa
Droxidopa
Entacapone
Norepinephrine
More general drug interventions related to this trial
Adrenergic Agents
Adrenergic Agonists
Adrenergic alpha-Agonists
Anti-Dyskinesia Agents
Antiparkinson Agents
Autonomic Agents
Cardiovascular Agents
Central Nervous System Agents
Dopamine Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sympathomimetics
Therapeutic Uses
Vasoconstrictor Agents
Sponsors listed in this trial
National Institute of Neurological Disorders and Stroke (NINDS)
Back to top of Main Content
